Cargando…

Analysis of the antitumor activity of gemcitabine and carboplatin against ovarian clear-cell carcinoma using the DNA damage marker γH2AX

BACKGROUND: Differences in the incidence and type of DNA damage induced by antitumor agents for ovarian clear-cell carcinoma (CCC) were determined in two CCC cell lines, using γH2AX. MATERIALS AND METHODS: The antitumor activity of gemcitabine (GEM) and carboplatin (CBDCA) were examined using cultur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takatori, Eriko, Shoji, Tadahiro, Sawai, Takashi, Kurose, Akira, Sugiyama, Toru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718840/ https://www.ncbi.nlm.nih.gov/pubmed/23898228 http://dx.doi.org/10.2147/OTT.S44021

Ejemplares similares

Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents
por: Takatori, Eriko, et al.
Publicado: (2012)

Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report
por: Takatori, Eriko, et al.
Publicado: (2014)

A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report
por: Takatori, Eriko, et al.
Publicado: (2015)

A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review
por: Shoji, Tadahiro, et al.
Publicado: (2016)

Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Clinical Significance of Atypical Glandular Cells in the Bethesda System 2001: A Comparison with the Histopathological Diagnosis of Surgically Resected Specimens
por: Shoji, Tadahiro, et al.
Publicado: (2014)

Safe administration of bevacizumab combination chemotherapy for the patients with recurrent cervical cancer after pelvic radiotherapy: Two case reports
por: Shoji, Tadahiro, et al.
Publicado: (2018)

Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
por: Shoji, Tadahiro, et al.
Publicado: (2012)

Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration
por: Giovannoni, Sara, et al.
Publicado: (2014)

A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
por: Shoji, Tadahiro, et al.
Publicado: (2014)

Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801
por: Takayama, Koichi, et al.
Publicado: (2020)

Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer
por: Shoji, Tadahiro, et al.
Publicado: (2021)

A retrospective study of neoadjuvant chemotherapy plus radical hysterectomy versus radical hysterectomy alone in patients with stage II cervical squamous cell carcinoma presenting as a bulky mass
por: Takatori, Eriko, et al.
Publicado: (2016)

A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study)
por: Nagasawa, Takayuki, et al.
Publicado: (2023)

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
por: Ayhan, Sevgi, et al.
Publicado: (2023)

The γH2AX DNA damage assay from a drop of blood
por: Heylmann, Daniel, et al.
Publicado: (2016)

Genome-wide profiles of H2AX and γ-H2AX differentiate endogenous and exogenous DNA damage hotspots in human cells
por: Seo, Jungmin, et al.
Publicado: (2012)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer
por: Penson, Richard T, et al.
Publicado: (2023)

Genome Instability and γH2AX
por: Georgoulis, Anastasios, et al.
Publicado: (2017)

Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass
por: Shoji, Tadahiro, et al.
Publicado: (2016)

DNA Damage Sensor γ-H2AX Is Increased in Preneoplastic Lesions of Hepatocellular Carcinoma
por: Matsuda, Yasunobu, et al.
Publicado: (2013)

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
por: Helbekkmo, N, et al.
Publicado: (2007)

Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Carboplatin Effects Against Ovarian Cancer()
por: Yu, Jun, et al.
Publicado: (2013)

Genome-wide multi-parametric analysis of H2AX or γH2AX distributions during ionizing radiation-induced DNA damage response
por: Natale, Francesco, et al.
Publicado: (2013)

The association of four genetic variants with myelosuppression in gemcitabine‐treated Japanese is not evident in gemcitabine/carboplatin‐treated Swedes
por: Björn, Niclas, et al.
Publicado: (2022)

Antitumor Activity of the Carboplatin-α-Cyclodextrin Adduct
por: Liu, Weiping, et al.
Publicado: (1997)

A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease
por: Shoji, Tadahiro, et al.
Publicado: (2019)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

Comment on ‘The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer‘
por: Kitchen, D, et al.
Publicado: (2013)

Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2013)

The HINT1 tumor suppressor regulates both γ-H2AX and ATM in response to DNA damage
por: Li, Haiyang, et al.
Publicado: (2008)

PP4 is a γH2AX phosphatase required for recovery from the DNA damage checkpoint
por: Nakada, Shinichiro, et al.
Publicado: (2008)

Serum C-reactive protein level is a significant prognostic indicator in patients with advanced urothelial cancer treated with gemcitabine-cisplatin or carboplatin – preliminary results
por: Morizane, Shuichi, et al.
Publicado: (2012)

γH2AX spreading linked to homology search
por: Renkawitz, Jörg, et al.
Publicado: (2013)

Effects of sequential paclitaxel–carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study
por: Wang, Fei, et al.
Publicado: (2016)

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
por: Yardley, D A, et al.
Publicado: (2018)

Advantages of evaluating γH2AX induction in non-clinical drug development
por: Motoyama, Shigeki, et al.
Publicado: (2018)

Magnetic delivery of antitumor carboplatin by using PEGylated-Niosomes
por: Davarpanah, Fereshteh, et al.
Publicado: (2018)

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer
por: Harries, M, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_q73dqmjb2ckd1tkln2gg482lto